Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
no-carrier-added lutetium-177
- Development stage
- Unknown
- Lead developer
- ITM Isotope Technologies Munich
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
No-carrier-added lutetium-177 (n.c.a. Lu-177) is a high-purity radioisotope produced by the neutron irradiation of enriched ytterbium-176, followed by chemical separation. This production route is distinct from the carrier-added method as it yields Lu-177 with high specific activity and eliminates the long-lived radioactive impurity lutetium-177m, which simplifies clinical logistics and waste management. As a beta-emitting radionuclide with a half-life of approximately 6.6 days, it serves as the active pharmaceutical ingredient or precursor in targeted radionuclide therapies (TRT). It is chemically conjugated to targeting molecules, such as peptides (e.g., PSMA-617, DOTATATE) or monoclonal antibodies, to deliver localized ionizing radiation to malignant cells. Its primary applications include the treatment of neuroendocrine tumors and metastatic castration-resistant prostate cancer.
- Brand names
- EndolucinBeta
- Other names
- lutetium (177Lu) chloridenon-carrier-added lutetium-177high specific activity lutetium-177
02
Targets
DNA
Beyond the preview
Go deeper on no-carrier-added lutetium-177.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on no-carrier-added lutetium-177.